MedTrace Logo

Role of Early Versus Late Switch to Lapatinib-Capecitabine (TYCO)

NCT01160094 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 288

Last updated 2016-03-28

No results posted yet for this study

Summary

It will be conducted as an international multicenter prospective observational cohort study in a population of ErbB2 positive metastatic breast cancer patients, whose disease has progressed after trastuzumab-containing regimen, comparing outcomes in two groups: Group 1: patients receiving Lapatinib-capecitabine immediately after 1st Trastuzumab progression (second line treatment), and Group 2: patients receiving Lapatinib-capecitabine after 2 or more lines of treatment after 1st trastuzumab progression (third line or greater).

Conditions

Interventions

DRUG

Treatment

patients treated with Lapatinib-Capecitabine after Trastuzumab Progression

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-02-28
Primary Completion
2013-07-31
Completion
2013-07-31

Countries

  • Colombia
  • Saudi Arabia

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01160094 on ClinicalTrials.gov